Wachid Putranto

Dr. Wachid Putranto

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in Narra J
Verified
Journal Article
Open access
PDF file
JFJonny Karunia Fajar
Jonny Karunia Fajar
FTFredo Tamara
Fredo Tamara
WPWachid Putranto
Wachid Putranto
Nurhasan Agung PrabowoNurhasan Agung Prabowo
Nurhasan Agung Prabowo
Harapan HarapanHarapan Harapan
Harapan Harapan
The insertion or deletion polymorphisms of the angiotensin-converting enzyme gene (ACE I/D) have been the subject of significant research related to coronavirus disease 2019 (COVID-19). Despite this, the findings have remained uncertain and debatable. The aim of this study was to determine the associations between the ACE I/D polymorphisms and the susceptibility as well as the severity of COVID-19. A meta-analysis study (PROSPERO: CRD42022384562) was conducted by searching the articles published on PubMed, Scopus, and Embase as of May 15, 2023. Information regarding the impact of ACE I/D variant on the susceptibility to COVID-19 and its severity was collected and analyzed utilizing the Mantel-Haenszel method with a random effects model or fixed effects model, depending on the presence or absence of heterogeneity. Out of 3,335 articles, 21 articles were included, of which 13 investigated the association between ACE I/D and the risk of COVID-19 infection and 18 of them examined its influence on disease severity. The D allele of ACE increased risk of COVID-19 infection (OR: 1.41; 95%CI: 1.08–1.85; p-Egger: 0.0676; p-Heterogeneity: <0.001; p=0.0120), while ACE I allele (OR: 0.71; 95%CI: 0.54–0.93; p-Egger: 0.0676; p-Heterogeneity: <0.001; p=0.012) and II genotype (OR: 0.55; 95%CI: 0.34–0.87; p-Egger: 0.200; p-Heterogeneity: <0.001; p=0.011) decreased the risk of infection. Additionally, there was a notable association between the ACE ID genotype and an elevated likelihood of experiencing severe COVID-19 within the Asian population (OR: 1.46; 95%CI: 1.15–1.84; p-Egger: 0.092; p-Heterogeneity: 0.116; p=0.002). The presence of ACE I/D polymorphisms significantly influences the likelihood of being susceptible to and experiencing the severity of COVID-19.

23 September 2023 in Journal of Nephropathology
Verified
Journal Article
Open access
WPWachid Putranto
Wachid Putranto
GFGigih Fitriawan
Gigih Fitriawan
RDRatih Tri Kusuma Dewi
Ratih Tri Kusuma Dewi
ASAryo Suseno
Aryo Suseno
ANArief Nurudhin
Arief Nurudhin
YPYeremia Suryo Pratama
Yeremia Suryo Pratama
Introduction: Diabetic kidney disease (DKD) progression resulted in increased intrarenal oxidative stress and increased inflammatory resulting in further renal fibrosis. Achatina fulica mucus was regarded to exerts anti-oxidative and anti-inflammatory effect. Objectives: This study aims to observe the effect of administration of A. fulica mucus on oxidative stress and inflammation biomarkers in DKD-induced rats. Methods and Materials: In this study, we used 32 males white Wistar rats divided into four groups; a control, and other three different groups induced with 45 mg/kg streptozocin (STZ) and 110 mg/kg nicotinamide (NA) intra-peritoneally. Achatina fulica mucus was administered orally in the last groups; 3.5 mL/d (S1), and 7 mL/d (S2). Post-test measurement of inflammatory and oxidative biomarker was used to determine the outcome. Results: The study resulted in reduction of malondialdehyde (MDA), transforming growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α), high sensitivity C-reactive protein (hs-CRP), vascular endothelial growth factor (VEGF), and interleukin-1β (IL-1β) in A. fulica mucus administration in our STZ-NA induced rats, with higher dose of the mucus further reduce the inflammatory and oxidative stress biomarkers. Conclusion: Current study showed the potential of A. fulica mucus usage in future management of inflammation and oxidative stress in diabetes and DKD.

3 September 2024 in European Journal of Case Reports in Internal Medicine
Verified
Journal Article
Open access
PDF file
WPWachid Putranto
Wachid Putranto
YPYeremia Suryo Pratama
Yeremia Suryo Pratama
KKKrisandryka Krisandryka
Krisandryka Krisandryka
EPEko Adi Pangarso
Eko Adi Pangarso
MAMeira Dewi Kusuma Astuti
Meira Dewi Kusuma Astuti
NPNurhasan Agung Prabowo
Nurhasan Agung Prabowo
Background: The presentation of mineral bone disorder (MBD) in individuals with chronic kidney disease (CKD) may vary. Consequently, physicians should be capable of recognising this condition when there is a suspicion of its existence. This case report will describe a calcified maxilla tumour as a manifestation of CKD-MBD. Case description: Initially asymptomatic, a 32-year-old female presented with progressive swelling of the upper left jaw. She had a history of routine haemodialysis. Further laboratory, radiological, and histopathological workup revealed the mass was indeed calcified maxillary fibroma arising from the manifestation of CKD-MBD. Conclusion: This study underscores the significance of clinical comprehension of the broad-spectrum manifestations of CKD-MBD, including an initially asymptomatic mass. In addition, the screening of the patient’s biochemical was required to determine the necessity of early intervention and improve the patient’s outcome.


1 November 2025 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
CSCoana Sukmagautama
Coana Sukmagautama
RRReviono Reviono
Reviono Reviono
WPWachid Putranto
Wachid Putranto
EPEti P. Pamungkasari
Eti P. Pamungkasari
HHHartono Hartono
Hartono Hartono
PDParamasari Dirgahayu
Paramasari Dirgahayu
Context: Peptic ulcer remains a significant global health concern, particularly in low-resource settings. Conventional treatments are often associated with side effects and recurrence, prompting interest in herbal therapies such as Zingiber officinale (ginger). Aims: To explore the gastroprotective efficacy of Z. officinale in preclinical models of experimentally induced peptic ulcer. Methods: Electronic databases (Scopus, ScienceDirect, and PubMed) were searched for relevant studies published between 2015 and 2024. Eligible studies included rodent models of peptic ulcer treated with Z. officinale and reporting ulcer index outcomes. Risk of bias was assessed using SYRCLE’s tool, and meta-analysis was performed using Review Manager 5.4.1 software. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated using a random-effects model. Results: Five experimental animal studies from 2015 onwards to assess the gastroprotective effects of Z. officinale, involving 240 rodents with peptic ulcers induced via WIR stress, ethanol, HCl, or diclofenac, were included. Z. officinale, administered in various forms, significantly reduced ulcer severity compared to placebo (SMD = -5.35; 95% CI: -6.56 to -4.10; I² = 79%) and showed efficacy comparable to standard therapies (SMD = 2.88; 95% CI: 1.36 to 4.41; I² = 91) as proton pump inhibitor (PPI) and H2 blockers. Conclusions: Z. officinale exhibits significant gastroprotective activity in animal models of peptic ulcer. These findings support its potential as a candidate for further development in ulcer therapy, although standardized protocols and clinical trials are warranted.